Dry-blend recovery products containing L-ornithine alpha-ketoglutarate (2:1) are produced under a positive-pressure blending environment conditioned to 18–22 °C and RH ≤ 35%; the raw salt is pre-dried at 40 °C when incoming residual moisture exceeds 0.5 wt%. A typical direct-mix addition for a non-effervescent stick pack is 0.8–1.5 g per 15 g serving, equivalent to 5.3–10.0 wt%, while published dose-response data for athletic recovery products remains limited and no harmonized maximum intake exists. The finished dietary supplement is released under 21 CFR 111.105 and ISO 22000:2018, with uniformity assessed against USP 905 and powder flow characterized by USP 1174. On production-scale tumble blenders, hygroscopic bridging at the batch outlet is reduced by staged addition of fumed silica at 1.0–2.0 wt% after the active phase has passed through a 1.0 mm conical mill. The sequence terminates in a servo-driven vertical form-fill-seal line with a ±0.1 g weight tolerance, producing a non-effervescent recovery stick pack and a companion 00 hydroxypropyl methylcellulose capsule. Compliance in the EU depends on national competent authority notification because amino acid salts fall outside Annex II of Directive 2002/46/EC.

How Does the 2:1 Salt Constrain Osmolality in Ready-to-Hang Immunonutrition Batches?

Clinical enteral immunonutrition formulas for burn, trauma, and surgical patients are manufactured to the compositional rules of Regulation (EU) No 2016/128 for food for special medical purposes and, in the US, the medical food definition at 21 CFR 101.9(j)(8) under current good manufacturing practice in 21 CFR Part 117. In a 1.0 kcal/mL intact-protein tube-feeding batch, the 2:1 salt is added at 0.4–1.0 g per 100 mL, because the alpha-ketoglutarate moiety contributes to titratable acidity and shifts osmolality upward; release limits generally cap the product at 400–500 mOsm/kg depending on whether the label is restricted to tube-fed administration. The manufacturing sequence cold-dissolves the salt in deionized water before protein and oil phases are combined, then passes the mixture through a two-stage homogenizer at 180/30 bar and a plate UHT system at 138 °C for 5–10 s. Reducing sugars are limited in this process because the alpha-ketoglutarate fraction can enter Maillard browning during UHT holding; formulators typically replace dextrose with low-dextrose-equivalence maltodextrin or high-amylose starch. The terminal format is a ready-to-hang 500 mL or 1000 mL enteral feeding bag, with an oral sip-feed variant filled into 200 mL aseptic cups. Published clinical trials on ornithine alpha-ketoglutarate in burn and trauma populations have used oral or enteral doses up to 20 g/day, but published data for the exact 2:1 salt in commercial formula addition ratios is limited.

A spoonable medical nutrition cream intended for sarcopenic or dysphagic adults contains 1.0 g of L-ornithine alpha-ketoglutarate (2:1) per 200 g serving, a 0.5 wt% addition that remains compatible with a final product pH of 4.2–4.6. At higher addition levels, the free acidity of the alpha-ketoglutarate fraction lowers pH below 4.2 and forces additional sodium citrate buffer beyond 0.8 wt%, which can strip casein micelles and produce serum separation during storage. The product is manufactured under Regulation (EU) No 2016/128, 21 CFR 101.9(j)(8), and ISO 22000:2018, with the thermal process designed around the pH-controlled hurdle rather than full retort sterilization. Downstream processing uses a high-shear recirculation vessel at 1200–1800 rpm, followed by a plate heat exchanger at 85 °C for 12 min and hot-filling into multilayer polypropylene cups sealed with aluminum foil. The terminal finished format is a texture-modified, spoonable oral nutritional supplement cup labeled for use under medical supervision.

Wet-Mass Granulation Limits for High-Dose Capsule Blends Containing the 2:1 Salt

The capsule-grade granulate is formulated at 45–60 wt% active salt, 20–35 wt% microcrystalline cellulose, and 3.0–6.0 wt% croscarmellose sodium; wet massing moisture is kept between 18 wt% and 22 wt%, because lower moisture produces friable granules and higher moisture causes dosator sticking on the filling line. The granulation sequence runs a high-shear mixer with an impeller speed of 250 rpm and a chopper speed of 1500 rpm, followed by wet-milling through a 2.0 mm screen and fluid-bed drying at 45 °C until loss on drying falls to 1.5–2.0%. Release criteria include USP 905 for weight variation, USP 1174 flow characterization before encapsulation, and ICH Q3D elemental impurity screening on the raw salt; the production site operates under 21 CFR 111.105. The terminal dosage form is a two-piece hydroxypropyl methylcellulose capsule with a fill weight of 700 mg, yielding a non-gelatin high-dose amino acid recovery support format.

If a Low-pH Amino Acid Shot Is Produced by Tunnel Pasteurization, Buffering Prevents Alpha-Ketoglutarate Acid Release from the Salt

Low-pH nutricosmetic amino acid shots containing L-ornithine alpha-ketoglutarate (2:1) are compounded at 75–150 mg per 50 mL bottle, a range selected because higher additions depress pH and generate a sour taste unacceptable in a ready-to-drink format. The free acid released from the salt in aqueous solution is controlled with potassium citrate; the target pH is 4.2, and the buffer concentration is adjusted after the active phase has dissolved to avoid locally acidic zones that accelerate salt hydrolysis. The product is manufactured as a food supplement under 21 CFR 111.105 in the US, while EU marketing depends on national competent authority notification because this amino acid salt is not harmonized under Directive 2002/46/EC. Downstream processing consists of cold compounding, filling into polyethylene terephthalate bottles, and tunnel pasteurization at 72 °C for 2 min, after which the batch is cooled to 20 °C in a recirculating water bath. The terminal finished format is a buffered, low-pH amino acid shot positioned as a proline-precursor dietary supplement; published clinical data for beauty-from-within endpoints is limited for this specific salt.

What Triggers Concentration Segregation in Continuous Blending of Wound-Care Medical Food Powders?

Continuous blending of unflavored wound-care medical food powders containing 2.0–3.0 g of the 2:1 salt per 50 g serving (4–6 wt%) requires matched particle-size distributions across active, protein, and fiber fractions; segregation occurs when the active fraction is milled below 1.0 mm while the protein phase remains above 2.0 mm. The production line therefore uses loss-in-weight feeders calibrated to a ±2% feed accuracy into a continuous twin-screw blender, with the active fraction pre-granulated to a D50 of 1.25 mm before blending. The product is manufactured under 21 CFR 111.105, Regulation (EU) No 2016/128, and ISO 22000:2018, with the sachet atmosphere flushed to oxygen below 2% residual and humidity below 0.5% absolute. The downstream fill sequence uses a horizontal form-fill-seal line with photoelectric registration and a ±0.2 g fill weight limit on a 50 g target. The terminal finished format is a multilaminate aluminum sachet of unflavored powder for the dietary management of pressure injury and wound healing, labeled for use under medical supervision.